Hoxworth

Hoxworth Blood Center » Research & Education » Research » Publications and Patents

Publications and Patents

Publications

  1. Hegde S, Zheng Y, Cancelas JA. Novel blood derived hemostatic agents for bleeding therapy and prophylaxis.Curr Opin Hematol. 2022 Aug 4. Online ahead of print. PMID: 35942861 NIHMS1823634
  2. Cancelas JA, Genthe JR, Stolla M, Rugg N, Bailey SL, Nestheide S, Shaz B, Mack S, Schroeder K, Anani W, Szczepiorkowski ZM, Dumont LJ, Yegneswaran S, Corash L, Mufti N, Benjamin RJ, Erickson AC. Evaluation of amotosalen and UVA pathogen-reduced apheresis platelets after 7-day storage. Transfusion. 2022 Aug;62(8):1619-1629. PMID: 35808974. 
  3. Vogel M, Möhrle B, Sakk V, Brown A, Palmer A, Braumüller S, Huber-Lang M, Allgöwer A, Cancelas JA, Geiger H. A limited role for AMD3100 induced stem cell mobilization for modulation of thoracic trauma outcome. Shock. 2022 Jun 1;57(6):260-267. PMID: 35759306
  4. Nayak RC, Chang K, Singh AK, Kotlian M, Desai M, Wellendorf AM, Wunderlich M, Bartram J, Mizukawa B, Cuadrado M, Dexheimer P, Barski A, Bustelo XR, Nassar NN, Cancelas JA. Nuclear Vav3 is required for polycomb repression complex-1 activity in B-cell lymphoblastic leukemogenesis. Nat Commun 2022 Jun 1;13(1):3056. PMID: 35650206 PMC9160250
  5. Patritti Cram J, Wu J, Coover RA, Rizvi TA, Chaney KE, Ravindran R, Cancelas JA, Spinner RJ, Ratner N. Purinergic receptor P2RY14 cAMP signaling regulates Schwann cell precursor self-renewal, Schwann cell proliferation, and nerve tumor initiation in a mouse model of neurofibromatosis. Elife 2022 Mar 21;11:e73511. doi: 10.7554/eLife.73511. PMID: 35311647 PMC8959601
  6. Mock DM, Stowell SR, Franco RS, Kyosseva SB, Nalbant D, Schmidt RL, Cres GA, Strauss RG, Cancelas JA, von Goetz M, North AK, Widness JA. Antibodies against biotin-labeled red blood cells can shorten posttransfusion survival. Transfusion 2022 March 11 Epub. doi 10.1111/trf.16849 PMID: 35274303PMC9007277
  7. Hegde S, Gasilina A, Wunderlich M, Lin Y, Buchholzer M, Krumbach OHF, Akbarzadeh M, Ahmadian MR, Seibel W, Zheng Y, Perentesis JP, Mizukawa BE, Vinnedge LP, Cancelas JA, Nassar NN. Inhibition of the RacGEF VAV3 by the small molecule IODVA1 impedes RAC signaling and overcomes resistance to tyrosine kinase inhibition in acute lymphoblastic leukemia. Leukemia. 2022 Mar;36:637-647. PMID: 34711926 PMC8885421 
  8. Rubinstein JD, Lutzko C, Leemhuis T, Zhu X, Pham G, Ray LM, Thomas S, Dourson C, Wilhelm J, Lane A, Cancelas JA, Lipps D, Ferrell J, Hanley PJ, Keller MD, Bollard CM, Wang YM, Davies SM, Nelson AS, Grimley M. Scheduled administration of virus-specific T cells for viral prophylaxis after pediatric allogeneic stem cell transplant. Blood Adv May 10, 2022;6(9):2897-2907. PMID: 35108727 7 PMC9092421 
  9. Noel JG, Ramser SW, Pitstick L, Bonamer JP, Mackenzie B, Seu KG, Kalfa TA, Cancelas JA, Gardner JC. M-CSF supports medullary erythropoiesis and erythroid iron demand following burn injury through its activity on homeostatic iron recycling. Sci Rep. 2022 Jan 24;12(1):1235. PMID: 35075211 PMC8786861 
  10. Cancelas JA, Nestheide S, Rugg N, Eckerman A, MacDonald VW, Charles ML, Markstrom L, Atkinson AJ, King MR, Snyder M, Burgess D, Murto J, Valiyaveettil MK, Pehta JC, Penegon SA. Characterization and first-in-human clinical dose-escalation safety evaluation of a next-gen human freeze-dried plasma. Transfusion Feb 2022;62(2)406-17. PMID: 34951486
  11. Rubinstein JD, Jodele S, Heyenbruch D, Wilhelm J, Thomas S, Lutzko C, Zhu X, Leemhuis T, Cancelas JA, Keller M, Bollard CM, Hanley PJ, Boghdadly ZE, Mims A, Davies SM, Grimley MS, Nelson AS. Off the shelf third party virus specific T-cell therapy to treat JC polyomavirus infection in hematopoietic stem cell transplant recipients. Transplant Cell Ther 2022 Feb;28(2):116.e1-116.e7. PMID: 34785398
  12. Ohanian M, Cancelas JA, Davenport R, Pullarkat V, Hervig T, Broome C, Marek K, Kelly M, Gul Z, Rugg N, Nestheide S, Kinne B, Szczepiorkowski Z, Kantarjian H, Pehta J, Biehl R, Yu A, Aung F, Antebi B, Fitzpatrick GM. Freeze-dried platelets are a promising alternative in bleeding thrombocytopenic patients with hematological malignancies. Am J Hematol 2022 Mar 1;97(3):256-266. doi: 10.1002/ajh.26403 PMID: 34748664
  13. Rubinstein JD, Zhu X, Leemhuis T, Pham G, Ray L, Emberesh S, Jodele S, Thomas S, Cancelas JA, Bollard CM, Hanley PJ, Keller MD, Grimley O, Clark D, Clark T, Lindestam Arlehamn CS, Sette A, Davies SM, Nelson AS, Grimley MS, Lutzko C. Virus-specific T cells for adenovirus infection after stem cell transplantation are highly effective and class II HLA restricted. Blood Adv. 2021 Sep 14;5(17):3309-3321. PMID: 34473237 PMC8525242
  14. Adori C, Daraio T, Kuiper R, Barde S, Horvathova L, Yoshitake T, Ihnatko R, Valladolid-Acebes I, Vercruysse P, Wellendorf AM, Gramignoli R, Bozoky B, Kehr J, Theodorsson E, Cancelas JA, Mravec B, Jorns C, Ellis E, Mulder J, Uhlén M, Bark C, Hökfelt T. Disorganization and degeneration of liver sympathetic innervations in nonalcoholic fatty liver disease revealed by 3D imaging. Sci Adv. 2021 Jul 21;7(30):eabg5733. PMID: 34290096 PMC8294768. (The protocol for this paper may be requested at Request a Protocol - Bio-protocol)
  15. Fan Y, Teng Y, Loison F, Pang A, Kasorn A, Shao X, Zhang C, Ren Q, Yu H, Zheng Y, Cancelas JA, Manis J, Chai L, Park SY, Zhao L, Xu Y, Feng S, Silberstein LE, Ma F, Luo HR. Targeting multiple cell death pathways extends the shelf life and preserves the function of human and mouse neutrophils for transfusion. Sci Transl Med. 2021 Jul 28;13(604):eabb1069. PMID: 34321317 NIHMS 1734011
  16. Serrano-Lopez J, Hegde S, Kumar S, Serrano J, Fang J, Wellendorf AM, Roche PA, Rangel Y, Carrington LJ, Geiger H, Grimes HL, Luther S, Maillard I, Sanchez-Garcia J, Starczynowski DT, Cancelas JA. Inflammation rapidly recruits GMP and MDP from bone marrow into regional lymphatics. Elife 2021 Apr 8;10:e66190 PMID:33830019 PMC8137144 
  17. Davis G, York AJ, Bacon WC, Lin SC, McNeal MM, Yarawsky AE, Maciag JJ, Miller JLC, Locker KCS, Bailey M, Stone R, Hall M, Gonzalez J, Sproles A, Woodle ES, Safier K, Justus KA, Spearman P, Ware RE, Cancelas JA, Jordan MB, Herr AB, Hildeman DA, Molkentin JD. Seroprevalence of SARS-CoV-2 infection in Cincinnati Ohio USA from August to December 2020. PLoS One 2021 Jul 14;16(7):e0254667. PMID: 34260645  PMC8279307
  18. Singh AK, Cancelas JA. Mitochondria transfer in bone marrow hematopoietic activity. Curr Stem Cell Rep 2021 Mar;7:1-12. NIHMS1829725
  19. Hegde S, Wellendorf A, Zheng Y, Cancelas JA. Antioxidant prevents clearance of hemostatically competent platelets after long-term cold storage. Transfusion. 2021 Feb;61(2):557-567. PMID: 33247486. PMC8006927
  20. Prus K, Alquist CR, Cancelas JA, Oh D. Decrease in serum antibodies to SARS-CoV-2 in convalescent plasma donors over time. Transfusion 2021 Feb;61(2):651-4. PMID: 33616966 PMC8014079
  21. Golan K, Singh AK, Kollet O, Bertagna M, Althoff MJ, Khatib-Massalha E, Petrovich-Kopitman E, Wellendorf AM, Massalha H, Levin-Zaidman S, Dadosh T, Bohan B, Gawali MV, Dasgupta B, Lapidot T, Cancelas JA. Bone marrow regeneration requires mitochondrial transfer from donor Cx43-expressing hematopoietic progenitors to stroma. Blood 2020 Dec 3;136(23):2607-19. PMID: 32929449 PMC7735163
  22. Nelson AS, Heyenbruch D, Rubinstein JD, Sabulski A, Jodele S, Thomas S, Lutzko C, Zhu X, Leemhuis T, Cancelas JA, Keller M, Bollard CM, Hanley PJ, Davies SM, Grimley MS. Virus-specific T-cell therapy to treat BK polyomavirus infection in bone marrow and solid organ transplant recipients. Blood Adv 2020 Nov 24;4(22):5745-5754. PMID: 33216887 PMC7686882 
  23. Govindarajah V, Lee J-M, Solomon M, Goddard B, Nayak N, Nattamai K, Geiger H, Salomonis N, Cancelas JA, Reynaud D. FOXO activity adaptation safeguards the hematopoietic stem cell compartment in hyperglycemia. Blood Adv 2020 Nov 10;4(21):5512-26. PMID: 33166407 PMC7656925 
  24. Kelly K, Cancelas JA, Szczepiorkowski ZM, Dumont DF, Rugg N, Dumont LJ. Frozen platelets - Development and future directions. Transfus Med Rev 2020 Oct;34(4)286-93. PMID: 33317698
  25. Althoff MJ, Nayak RC, Hegde S, Wellendorf AM, Bohan B, Filippi MD, Xin M, Lu QR, Geiger H, Zheng Y, Diaz-Meco MT, Moscat J, Cancelas JA. Yap1-Scribble polarization is required for hematopoietic stem cell division and fate. Blood 2020 Oct 20;136(16):1824-1836. PMID: 32483624 PMC7568035
  26. Boucher AA, Luchtman-Jones L, Palumbo JS, Cancelas JA, Abu-El-Haija M, Jenkins TM, Lin TK, Nathan JD. Extreme thrombocytosis after pediatric pancreatectomy with islet autotransplantation is unique compared to other postsplenectomy states. J Pediatr Surg. 2020 Aug;55(8):1645-50. PMID: 31677823 
  27. Rubinstein JD, Zhu X, Lutzko C, Leemhuis T, Cancelas JA, Jodele S, Bollard CM, Hanley PJ, Davies SM, Grimley MS, Nelson AS. Complement inhibition does not impair the clinical antiviral capabilities of virus-specific T-cell therapy. Blood Adv 2020 Jul 28;4(14):3252-3257. PMID: 32697816 PMC7391136 
  28. DʼAlessandro A, Yoshida T, Nestheide S, Nemkov T, Stocker S, Stefanoni D, Mohmoud F, Rugg N, Dunham A, Cancelas JA. Hypoxic storage of red blood cells improves metabolism and post-transfusion recovery.Transfusion. 2020 Apr;60(4):786-798. PMID: 32104927 PMC7899235
  29. Gasilina A, Premnauth G, Gurjar P, Biesiada J, Hegde S, Milewski D, Ma G, Kalin TV, Merino E, Meller J, Seibel W, Cancelas JA, Vinnedge LP, Nassar NN. IODVA1, a guanidinobenzimidazole derivative, targets Rac activity and Ras-driven cancer models. PLoS One. 2020 Mar 12;15(3):e0229801. PMID: 32163428 PMC7067412
  30. Yazer MH, Spinella PC, Doyle L, Kaufman RM, Dunn R, Hess JR, Filho LA, Fontaine M, Gathof B, Jackson B, Murphy MF, et al. Biomedical Excellence for Safer Transfusion Collaborative; Appendix. Members of the Biomedical Excellence for Safer Transfusion Collaborative. Transfusion of uncrossmatched Group O erythrocyte-containing products does not interfere with most ABO typings. Anesthesiology. 2020 Mar;132(3):525-34. doi: 10.1097/ALN.0000000000003069. PMID: 31789634
  31. Singh AK, Cancelas JA. Gap junctions in the bone marrow lympho-hematopoietic stem cell niche, leukemia progression, and chemoresistance. Int J Mol Sci. 2020 Jan 25;21(3). pii: E796. PMID: 31991829 PMC7038046
  32. Yu Y, Choi K, Wu J, Andreassen PR, Dexheimer PJ, Keddache M, Brems H, Spinner R, Cancelas JA, Martin LJ, Wallace MR, Legius E, Vogel KS, Ratner N. NF1 patient missense variants predict a role for ATM in modifying neurofibroma initiation. Acta Neuropathol 2020 Jan;139(1):157-74. PMID: 31664505 PMC7243727

 

Patents

Platelet Storage Methods and Compositions for Same. Zheng Y, Cancelas J.

US Patent 10405538 September 10, 2019. Publication: US010405538B2

Platelet Storage Methods and Compositions for Same. Zheng Y, Cancelas J.

US Patent 10028503 B2 July 24, 2018. Publication US010028503B2 Jul 24, 2018; US 2018/0139952 A1 May 24, 2018

Compositions and methods for slowing, preventing, or reversing platelet damage, particularly as may occur during blood banking or during refrigeration of platelets. The composition may include one or more of a RAC inhibitor, a CDC42 inhibitor, a RHOA inhibitor, or a combination thereof. The compositions may further include a pharmaceutically acceptable carrier.

Prolonged Storage of Red Blood Cells and Composition. Hess JR, Greenwalt TJ

Issue Date: November 21, 2000 US Patent # 6150085

Novel additive solutions that are useful for the storage of human red blood cells (RBCs) under refrigerated conditions. Also, a method of using the additive solutions in an appropriate volume to preserve RBCs at about 1 to 6°C for up to 10 weeks. The solutions and processes allow the viable storage of human RBCs for an extended period of time in a solution which is directly infusible in humans.

Preservation and Shelf Life Extension of Blood Cells. Hess JR, Greenwalt TJ

Issue Date: November 20, 2001 US Patent # 6447987

Preservative solutions that extend the useful shelf-life of red cells from the current 6 to 12 weeks. This intellectual property is shared by the US Army and the University of Cincinnati. Implementation is expected to save 600,000 units from outdating annually, to reduce seasonal shortages of blood, and to make autologous donor programs more efficient.

Compositions Substantially Free of Sodium Chloride and Methods fFor tThe Storage of Red Blood Cells. Hess JR, Greenwalt TJ

Issue Date: April 29, 2014 US Patent # 8709707

Composition of a solution for storage of red blood cells consisting essentially of: adenine; dextrose; a non- metabolizable membrane-protectant sugar; and a specifically defined pH buffering system. Improved methods for preserving red blood cells and methods for increasing the viability, membrane retention, and recoverability while suppressing apoptosis, hemolysis, and post-reinfusion clearance of stored red blood cells which utilize the novel compositions.